Enterprise record
Alpha ID: alpha:company:7bc1b655-1f18-4f22-85e3-69fae13fdce5Version: public-1
20 published Claims4 sources
The enterprise, in context.
Connect capital, control, accountability, and evidence.
Governance priorities
Capital allocationInspect reported performance, cash generation, and investment.Board accountabilityWho holds each mandate, and what evidence supports it?Ownership & votingSeparate economic interests from voting authority.Key Claims
Board and committees
Financial statements
Published financial observations retain their reported values, periods, and sources. Coverage may be partial; this is not a reconstructed complete financial statement.
All financials coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageControl and shareholders
Control and shareholders coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageCompensation
Compensation coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageAuditors, advisors and reporting
Auditors, advisors and reporting coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageLegal
Legal coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageAI governance
AI governance coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageEvidence, history and coverage
Additional published Claims
Published evidence records
4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
Alpha canonical company public projection
canonical identity · Source published: Date unavailable · Retrieved: Oct 1, 2026
Supports 3 claims
- Legal Name: Vanda Pharmaceuticals Inc. · Claim reviewed: Oct 1, 2026
- Entity Status: Public listing published · Claim reviewed: Oct 1, 2026
- Published Fact: US · Claim reviewed: Oct 1, 2026
SEC DEF 14A 0001628280-26-026893
sec def 14a · Source published: Apr 23, 2026 · Retrieved: Sep 14, 2026
Supports 9 claims
- Leadership Role: Mihael H. Polymeropoulos, M.D.: President, Chief Executive Officer and Chairman of the Board · Claim reviewed: Oct 1, 2026
- Leadership Role: Charles C. Duncan, Ph.D.: Director · Claim reviewed: Oct 1, 2026
- Leadership Role: Stephen Ray Mitchell, M.D.: Director · Claim reviewed: Oct 1, 2026
- Leadership Role: Tage Honoré, Ph.D., D.Sc.: Director · Claim reviewed: Oct 1, 2026
- Leadership Role: Gunther Birznieks: Senior Vice President, Business Development · Claim reviewed: Oct 1, 2026
- Leadership Role: Joakim Wijkstrom: Senior Vice President, Chief Marketing Officer · Claim reviewed: Oct 1, 2026
- Leadership Role: Kevin Moran: Senior Vice President, Chief Financial Officer and Treasurer · Claim reviewed: Oct 1, 2026
- Leadership Role: Mihael H. Polymeropoulos, M.D.: President, Chief Executive Officer and Chairman of the Board · Claim reviewed: Oct 1, 2026
- Leadership Role: Timothy Williams: Senior Vice President, General Counsel and Secretary · Claim reviewed: Oct 1, 2026
DEF 14A vnda-20260423.htm
sec proxy · Source published: Apr 23, 2026 · Retrieved: Sep 2, 2026
Supports 6 claims
- Leadership Role: Anne Sempowski Ward: Director · Claim reviewed: Oct 1, 2026
- Leadership Role: Charles C. Duncan: Director · Claim reviewed: Oct 1, 2026
- Leadership Role: Mihael H. Polymeropoulos: Director · Claim reviewed: Oct 1, 2026
- Leadership Role: Phaedra S. Chrousos: Director · Claim reviewed: Oct 1, 2026
- Leadership Role: Richard W. Dugan: Director · Claim reviewed: Oct 1, 2026
- Leadership Role: Stephen Ray Mitchell: Director · Claim reviewed: Oct 1, 2026
Granted in February 2026 (for 2025 Compensation) Committee
sec proxy · Source published: Date unavailable · Retrieved: Date unavailable
Supports 2 claims
- Committee Record: Granted in February 2026 (for 2025 Compensation) Committee: Chair not stated; Members Mihael H. Polymeropoulos · Claim reviewed: Oct 1, 2026
- Committee Appointment: Mihael H. Polymeropoulos: member, Granted in February 2026 (for 2025 Compensation) Committee · Claim reviewed: Oct 1, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
source reported
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-10-01
- Board and committees
- published
- Financial statements
- not observed
- Control and shareholders
- not observed
- Compensation
- not observed
- Auditors, advisors and reporting
- not observed
- Legal
- not observed
- AI governance
- not observed